Intraoperative Versus Postoperative Thymoglobulin in Lung Transplantation

Withdrawn before enrolling · Phase 3 · Has a placebo group

Conditions studied: Lung Transplant

In brief

The purpose of this study is to take a population of lung transplant recipients who meet UCLA criteria for induction chemotherapy with thymoglobulin and prospectively study weather giving the first dose intraoperatively versus postoperatively makes a difference with how patients do during and after lung transplantation.

Key facts

Study ID

NCT00592306

Run by

University of California, Los Angeles

People needed

0

Starts

2006-01-01

Expected to finish

2010-09-01

Last updated by the study team

2020-09-10

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• On a voluntary basis, all patients eligible for bilateral lung transplantation between the ages of 18-65 years (inclusive)

You may not qualify if…

• Have any known allergy to horse or rabbit antithymocyte polyclonal agents
• Have a preoperative platelet count less then 100,000/mm3
• Are recipients of multiple organ transplants (either simultaneous or sequential)
• Are recipients of a single lung transplantation
• Have a contraindication to rabbit antithymocyte globulin based on judgement of the investigators (i.e. bleeding diathesis or overwhelming risk of intense immunosuppression) including the following patients: greater than 65 years of age, prior diagnosis of malignancy (with the exception skin malignancies), underlying suppurative lung disease (i.e. bronchiectasis, cystic fibrosis, etc.).

Where it is running

• Departments of Pulmonary and Critical Care, Cardiothoracic Surgery and Infectious Diseases at David Geffen School of Medicine at UCLA — Los Angeles, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.